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Renal Involvement in Systemic 
Sclerosis
Tomas Soukup, Jan Toms, Sabina Oreska, Eva Honsova 
and Roman Safranek
Abstract
Scleroderma renal crisis (SRC) is classical renal disease in systemic sclerosis 
(SSc). SRC is a relatively rare manifestation, approximately in 5% of patients. In 
terms of severity, manifestation in the form of SRC is the most common cause of 
acute organ failure. In SSc patients, SRC is defined as a new onset of accelerated 
arterial hypertension and rapidly progressive anuric or oliguric renal failure. SRC 
is primarily vascular injury with increased activity of the renin-angiotensin activ-
ity. These events lead to release or activation of cytokines and growth factors that 
result in the typical proliferative vascular lesions. Successful approach is routine 
use of angiotensin-converting enzyme inhibitors in the treatment of SRC (except 
prevention) and other advances in renal replacement therapy in SSc management. 
It is crucial to detect manifestations of SRC early and to manage appropriately in 
collaboration with intensive care medicine, cardiologists, and nephrologists. In 
contrast to SRC, clinical presentation of interstitial renal disease is poor, often 
without evidence of renal abnormality. Interestingly, other renal manifestations 
are glomerulonephritis and vasculitis. These manifestations are associated with 
overlapping mechanisms. The objective of this chapter is to focus on actual knowl-
edge about the renal involvement in SSc and current treatment principles and 
possibilities.
Keywords: kidney, systemic sclerosis, scleroderma renal crisis, glomerulonephritis, 
diagnosis, management
1. Introduction
Systemic sclerosis (SSc) leads to morbidity and mortality through a combination 
of inflammation, fibrosis, and vascular damage leading to internal organ compli-
cations affecting the heart, lung, bowel, and kidneys. In SSc, we observe kidney 
involvement as three main clinical situations described below.
Most often, SSc causes a range of renal manifestations, which occur in both 
subsets of the disease: limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) 
subsets.
As overlaps are often seen in connective tissue diseases, SSc should be associ-
ated with other immunological features of renal disease findings typical for sys-
temic lupus erythematosus (as lupus glomerulonephritis) and ANCA-associated 
vasculitis/glomerulonephritis.
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Scleroderma renal crisis (SRC) is a dramatic and classical scleroderma mani-
festation, historically known as dominant cause of scleroderma-related death. 
Currently, the leading causes of death in scleroderma are pulmonary fibrosis and 
pulmonary arterial hypertension [1]. Regardless, one-year SRC outcomes remain 
poor, with over 30% mortality and 25% of patients remaining dialysis-dependent.
To make the summary complete, possible drug-related adverse events including 
from toxic renal involvement to renal acute renal failure must be mentioned.
2. Scleroderma renal crisis
2.1 Epidemiology
SRC occurs usually in early dcSSc (11%), as compared to patients with lcSSc 
(4%) [2, 3]. SRC is more common in rapidly progressing disease, SRC was previ-
ously reported up to 25% of SSc, but over time, it was found that incidence of renal 
crisis appeared to have decreased since improvement of early diagnostics [1].
Historically, study of Steen and Medsger [4] presented change of mortality causes 
during 1972–2002 years. This study showed that SRC as the cause decreased from 42 
to 6% of SSc-related deaths, while the proportion of other causes of death increased: 
pulmonary fibrosis rose from 6 to 33% and pulmonary arterial hypertension from 22 
to 28%. Large data were obtained prospectively followed in the EULAR Scleroderma 
Trials and Research (EUSTAR) cohort. The EUSTAR database was inaugurated in 
June 2004 and represents a multinational, prospective, and open SSc cohort [5]. 
According to EUSTAR data, SSc-related deaths include pulmonary fibrosis 19%, 
pulmonary arterial hypertension 14%, arrhythmia 6%, heart failure 7%, and SRC 
4%. Non–SSc-related deaths in total 4% include infection 13%, malignancy 13%, and 
cardiovascular 12%. Renal causes accounted for the death of 10 patients (4%), all due 
to renal crisis. Renal crisis was fatal in 16% of all patients experiencing renal crisis [5].
2.2 Pathogenesis of scleroderma renal crisis
Pathogenesis is characterized by series of insults (Figure 1):
• Changes in intima and endothelium: Initially, there is injury to the endothelial cells 
with intimal thickening and proliferation in the arcuate and interlobular arteries [6].
• Absence of inflammation: There is a notable absence of inflammatory cells (lym-
phocytes and monocytes) in the renal vasculature [6].
• Vascular injury: Platelet factors are released causing increased vascular perme-
ability, fibrin deposition, and collagen formation, which lead to further luminal 
narrowing [6].
• Renal ischemia: Narrowed renal arterioles decrease renal cortical blood flow [6].
• Activation of renin: Renal ischemia and episodic renal vasospasm “renal Raynaud 
phenomenon” contribute to decrease of blood flow. Decreased renal blood flow 
causes hyperplasia of the juxtaglomerular apparatus and release of renin [6].
• Secondary small vessel changes: endothelial injury is associated with thrombus 
formation. Intravascular thrombi and mucoid intimal edema may be seen 
in renal histology. Small vessel thrombi are more abundant than glomerular 
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thrombi (unlike the pathology seen in hemolytic-uremic syndrome and throm-
botic thrombocytopenic purpura) [7].
2.3 Renal histopathology
Histopathological findings of SRC are more frequently manifested by severe 
involvement of small arteries and arterioles. Early vascular changes are character-
ized by intimal accumulation of myxoid material in the interlobular and arcuate 
arteries, which results in severe luminal narrowing (Figure 2). Sometimes micro-
thrombi are developed in the affected vessels and fragmented red blood cells can be 
Figure 1. 
The mechanisms in the pathogenesis of SRC. Adapted from Steen et al. [8].
Figure 2. 
Early vascular changes are characterized by intimal accumulation of pale myxoid material in the small artery, 
which results in severe luminal narrowing (Methenamine-silver stain).
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Figure 3. 
Two types of glomerular injury associated with scleroderma renal crisis. Ischemic collapse of glomerulus with 
wrinkling of glomerular basement membrane corresponds to arterial stenosis.
Figure 4. 
Two types of glomerular injury associated with scleroderma renal crisis. Thrombotic microangiopathy 
with occlusion of outgoing arteriole is characterized by the congestion and hemorrhagic necrosis of the tuft 
(Methenamine-silver stain).
Figure 5. 
Prominent intimal concentric lamination within an interlobular artery (arterial onion skin lesion) with 
irreversible reduction of the arterial lumen (Methenamine-silver stain).
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seen in vessel wall. Microthrombi in arterioles can also progress to the glomeruli. 
When the arterioles incoming to glomeruli are predominantly affected, the mor-
phological features in glomeruli are characterized by ischemia with wrinkling of 
glomerular basement membrane and ischemic collapses of glomeruli (Figure 3). 
When microthrombi are developed mainly in outgoing arterioles, the correspond-
ing pathology is severe congestion and hemorrhagic necrosis of the tufts (Figure 4).
Later arterial injury is characterized by change of edematous mucoid intima to 
the concentric lamination and so called onion skin lesion (Figure 5) with significant 
luminal reduction. In glomeruli, the lesion is represented by double contouring of 
glomerular basement membrane (as a result of prolonged or repeated endothelial 
injury) and segmental or global sclerotic lesions.
Because blood supply in the kidney is represented by end vessels without collat-
erals, each area of kidney tissue after arterial luminal narrowing must suffer from 
severe ischemia or even tissue necrosis. In histopathology, pronounced ischemia 
leads to tubular injury in the intersticium and tubular atrophy with interstitial 
fibrosis in the course of time.
Since none of these findings are specific for SRC, the pathological diagnosis 
must be supported by appropriate clinical and serological data [9].
Histopathology: with courtesy of Eva Honsová, MD., PhD. Department of 
Pathology IKEM, Prague.
2.4 Definition, diagnosis, and classification
SRC is defined as new onset of accelerated arterial hypertension and rapidly 
progressive oliguric renal failure during the course of SSc. There are differences 
between the criteria used to define SRC [1]. Occasionally, more modest elevations in 
blood pressure and renal dysfunction and at times normotensive presentations were 
found [9, 10]. The diagnosis is complicated in the case of malignant hypertension 
with absence of kidney impairment.
SRC was defined in a minority of studies and criteria were heterogeneous [10]. 
It is a problem to establish criteria for SRC, because the clinical spectrum of SRC is 
broad, ranging from accelerated hypertension to normotensive patients 7% [10]. 
Arterial hypertension is a typical symptom in SRC accompanied by classical compli-
cations such as hypertensive encephalopathy, retinopathy, congestive heart failure, 
hemolysis, etc. Diagnosis of SRC in patients without pre-existing SSc diagnosis and in 
normotensive SRC patients is difficult, mainly in the absence of renal biopsy [10, 11].
Only one study up to now has partially validated criteria for SRC (Table 1) [8]. 
It was proposed by experts in 2003. It included items for systolic and diastolic blood 
pressure, serum creatinine, proteinuria, hematuria, microangiopathic hemolytic ane-
mia, and renal histopathology. These are known as the Ancona criteria for SRC [8].
Recently, the Scleroderma Clinical Trials Consortium (SCTC) and Scleroderma 
Renal Crisis Working Group generate a core set of items to develop classification criteria 
for SRC using Delphi methodology. The final core set of items to develop classification 
criteria for SRC contains domains: blood pressure arise, kidney impairment, hema-
tological changes, thrombotic microangiopathy, and organ dysfunction. A consensus 
definition of SRC is urgently needed to standardize data collection on SRC [9].
Novel concepts of SRC classification included the stratification of SRC:
• definite SRC: defined as at least two of: new onset hypertension, microangio-
pathic hemolytic anemia (MAHA), and rising creatinine
• subacute forms of SRC: such as hypertension, renal insufficiency, and renal sedi-
ment changes in the absence of microangiopathic hemolytic anemia [9, 10]
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New concept also includes the addition of ACE inhibitor responsiveness as a 
characteristic of hypertension (in probable SRC) and the addition of more specific 
time frames for measurement of blood pressure (taken twice, 2 hours apart, within 
3 days of first event-associated observation) [10].
In addition to heterogeneity and rarity, the absence of a gold standard and clas-
sification criteria are important challenges for research on SRC. The development 
of new criteria is important to improve the definition of normotensive SRC. In this 
case, performing kidney biopsy and examination of biomarkers (including anti-
RNA III polymerase) are important and promising.
2.5 Role of kidney biopsy in diagnosis of scleroderma renal crisis
Kidney biopsy is not mandatory for diagnosis of SRC. In patients at risk of 
SRC with its typical clinical presentation, kidney biopsy is usually not performed. 
However, it should be considered in all patients with atypical presentation and 
findings, especially in normotensive patients, patients with ANCA positivity, severe 
proteinuria, and nephrotic syndrome.
In most patients, we cannot perform kidney biopsy immediately as severe 
hypertension and frequently present thrombocytopenia significantly increase the 
risk of bleeding. Biopsy is usually performed within a few days after blood pressure 
correction and is done with reasonably low risk in patients with blood pressure 
below 160/90 mmHg and thrombocyte count above 100 × 109/l.
SRC is defined as following, requiring both:
A new onset of blood pressure >150/85 mm Hg obtained at least twice over a consecutive 24-hour period. 
This blood pressure is chosen because it is defined by the New York Heart Association as significant 
hypertension.
Decrease in the renal function as defined by a decrement of at least 10% in the estimated GFR (eGFR) or 
GFR of <90 (mL/min/1.73 m2. When possible, a repeat serum creatinine and recalculation of the GFR should 
be obtained to corroborate the initial results.
In order to corroborate further the occurrence of acute renal crisis, it would be desirable to have any of 
the following, if available:
• new onset of urinary red blood cells (excluding other causes)
• flash pulmonary edema
• oliguria or anuria
• microangiopathic hemolytic anemia on blood smear
• retinopathy typical of acute hypertensive crisis
• renal biopsy with typical features including onion skin proliferation within the walls of internal arteries 
and arterioles, fibrinoid necrosis, and glomerular shrinkage
Notes
• Cases of typical SRC histological appearance have been associated with scleroderma in the absence of 
hypertension; these cases of normotensive SRC are reported to have a particularly poor outcome, and 
their precise relationship to the more typical hypertensive SRC is not known. Normotensive SRC was 
observed in glucocorticoid scleroderma users.
• Up to one fifth of cases of SRC with hypertension have been identified as the presenting feature of 
systemic sclerosis, and so, in these cases, pre-existing diagnosis of systemic sclerosis will not be present.
SRC, scleroderma renal crisis; GFR, glomerular filtration rate.
Table 1. 
Clinical criteria for definition of scleroderma renal crisis [1].
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2.6 Predictive and risk factors
Identification of SRC predictive factors (before the development of SRC) is 
essential (Table 2). The vast majority of SRC cases (75–80%) occur in patients 
with diffuse skin involvement, i.e., skin scleroderma proximal to knee and elbow 
(dcSSc patients), and rapid progression of skin thickening has been shown to be 
associated with the development of SRC [12]. Arthritis, palpable tendon friction 
rubs, swollen fingers, and distal parts of hands are routine syndrome in patients 
with early dcSSc [13]. Tendon friction rubs were confirmed to be an independent 
predictor of SRC (HR: 2.33) [14].
SRC starts early, most often less than 4 years after the first SSc symptom, 
although SRC patients have minimal or even no skin changes at the time of the 
diagnosis of SRC. Males are proportionately more frequently affected than 
females [15].
On the other hand, patients previously called as CREST (calcino-
sis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly and 
Telangiectasia) rarely develop SRC. These patients are subgroup of lcSSc 
fundamentally [12].
When talking about risk factors of death, a history of renal crisis (HR 
2.89), presence of proteinuria (HR 3.09), elevated acute phase reactants (HR 
1.79), elevated creatine kinase (HR 1.73), and muscle weakness (HR 1.55) were 
associated with decreased survival [5, 16]. On the other hand, since the intro-
duction of ACE inhibitors, renal crisis appears to have become an increasingly 
less frequent terminal event [4]. In EUSTAR cohort, except one individual, all 
patients dying from renal crisis were on an ACE inhibitor at the time of death. 
Prednisone equivalents above 15 mg daily have been implicated in exacerbating 
SRC [5].
Several retrospective studies suggest that glucocorticoids are associated with a 
higher risk of SRC. Blood pressure and renal function should be carefully moni-
tored in patients with SSc treated with glucocorticoids [17]. Evidence regarding the 
impact of steroid use on the development of SRC comes mainly from retrospective 
studies, most of which showed significant association between steroid exposure and 
the occurrence of SRC [11, 15, 18–22].
A retrospective analysis including 140 patients with SRC showed that high 
doses of steroids (prednisone ≥30 mg/day) were used frequently in patients with 
SSc with normotensive SRC (64%) as compared with those with hypertensive 
SRC (16%) suggesting an association between the use of high-dose steroids and 
the risk of normotensive SRC, which is associated with worse prognosis [11].
Glucocorticoids are routinely used for the management of interstitial lung 
disease, puffy fingers, and skin involvement. These indications are not recom-
mended (because of insufficient evidence of efficacy); however, the experts 
recognize their use in everyday practice in the management of inflammatory 
manifestations such as musculoskeletal involvement (arthritis, tendonitis, 
myositis—in overlap with idiopathic inflammatory myopaties), pericarditis, 
pleuritis (in overlap with SLE), nonspecific symptoms such as skin itching/burn-
ing, fatigue, and appetite (with empiric basis) [17, 23]. Considering the potential 
risk of SRC associated with steroid use, the experts recommend that patients 
with SSc treated with steroids should be carefully monitored with respect to the 
development of SRC [17].
It can be summarized that glucocorticoids have a very narrow or no therapeutic 
opportunity in SSc.
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SRC patient-specific characteristics
Race—black
Gender—male sex
SSc characteristics
Short course of SSc
Diffuse cutaneous systemic scleroderma
Modified Rodnan skin score (>14 or 20)
Musculoskeletal contractures
Tendon friction rubs
Pitting scars on finger tips
Cardiopulmonary manifestation
Heart failure
Pericarditis
FVC <75% expected value
DLCO low/decrease
Muscle involvement
Muscle weakness
Higher creatine kinase level
Myalgias or myopathy
Arthritis/Arthralgias
Genetics and biomarkers
Anti-RNA polymerase III presence
Anti-RNA polymerase I/II/III presence
ELISA anti-RNA polymerase III ≥157 IU
Anti-centromere absence
Anti-nRNP presence
ANA speckled immunofluorescence
lipocalin-2 high levels [24]
sCD147 high levels [25]
angiogenin high levels
endothelin-1 high levels
HLA-DRB1*0407
HLA-DRB1*1304
Risk factors developed during SSc
Skin changes acceleration
Hemoglobin, thrombocyte decrease
Cardiac involvement—new
Pericarditis
Congestive heart failure
Drugs
Cocaine [26]
Glucocorticoid treatment
Cyclosporine A
Absence of calcium channel blocker
Factors without evidence of SRC risk
Previous blood pressure arise
Abnormal dip-stick and light proteinuria
Chronic elevation of serum creatinine
Presence of antibodies: anti-topoisomerase, anti-centromere
SRC, scleroderma renal crisis; SSc, systemic sclerosis; FVC, forced lung vital capacity; DLCO, diffusing capacity for 
carbon monoxide; RNA, ribonucleic acid; ELISA, enzyme-linked immunosorbent assay; nRNP, nucleic ribonucleic 
protein; ANA, antinuclear antibodies; HLA, human leucocyte antigen.
Table 2. 
Clinical and laboratory predictors of scleroderma renal crisis and worse outcome. Adapted from Bose et al. [6].
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2.7 Clinical manifestation of scleroderma renal crisis
2.7.1 Early symptoms
Sometimes SRC symptoms are nonspecific, for example, fatigue or not feeling 
well. Typically, patients complain of severe headache, blurred vision, or other 
encephalopathic symptoms with the onset of accelerated hypertension. Seizures 
may be also an early finding [1].
2.7.2 Blood pressure
Most patients have striking increase of blood pressure at the onset of SRC. Above 
90% patients have blood pressure levels >150/90 mm Hg, 30% have diastolic pres-
sure >120 mm Hg, and <10% of SSc have a normal blood pressure. In addition to 
thinking about absolute values, clinically important risk factors arise of 30 mmHg 
systolic and 20 mmHg diastolic blood pressure (repeatedly measured) [1].
2.7.3 Kidney injury, conditio sine qua non
Acute kidney injury is defined as any of the following: increase in serum creati-
nine by >26.5 μmol/L (> 0.3 mg/dl) within 48 hours; increase in serum creatinine 
to >1.5 times baseline, which is known or presumed to have occurred within the 
prior 7 days, and urine volume <0.5 ml/kg/h for 6 hours. This is the definition of 
acute kidney injury from the Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines [27].
2.7.4 Cardiopulmonary system
Patients with SRC often present with congestive heart failure presented as 
dyspnea, paroxysmal nocturnal dyspnea or pulmonary edema, serious ventricular 
arrhythmias, cardiac arrest, or large pericardial effusion [11]. Interestingly, this is 
primarily owing to the stress of hypertension on the heart, effects of hyperreninemia, 
and fluid overload secondary to oliguric renal failure. Some patients have primary 
scleroderma myocardial involvement contributing to these consecutive insults [1].
Acute pericarditis is diagnosed if the patient has at least 2 of the 4 follow-
ing criteria: (1) pericarditis chest pain; (2) pericardial rub; (3) new widespread 
ST-elevation or PR depression on electrocardiogram; (4) pericardial effusion (new 
or worsening) on cardiac echocardiography [1].
Pulmonary hemorrhage is a rare life-threatening status, which has occurred in 
several of SRC patients [10]. Etiopathogenesis is associated with pulmonary edema 
and hemorrhagic diathesis. In differential diagnosis, diffuse alveolar hemorrhagia and 
acute renal failure were rarely observed in cases of ANCA systemic vasculitis and SSc 
overlaps [28].
2.7.5 Target organ dysfunction
Typically, hypertensive retinopathy (hemorrhages, hard and soft (cotton wool) 
exudates, and/or disc edema, not attributable to other causes), confirmed by an 
ophthalmologist, is observed. Hypertensive encephalopathy is characterized by 
headache, altered mental status, seizures, visual disturbances, and/or other focal 
or diffuse neurologic signs not attributable to other causes. Acute congestive heart 
New Insights into Systemic Sclerosis
10
failure is characterized by typical symptoms (e.g., breathlessness, ankle swelling, 
and fatigue) that may be accompanied by signs (e.g., elevated jugular venous pres-
sure, pulmonary crackles, and peripheral edema) [1, 6].
2.8 Laboratory findings
2.8.1 Autoantibodies
Antinuclear antibodies (ANA) are hallmark of connective tissue diseases. In 
case of Raynaud phenomenon, puffy fingers, nailfold capillaroscopy finding 
with typical microvascular changes, and ANA can alert to the very early diagno-
sis of SSc and may determine etiology of malignant hypertension. ANA are seen 
in 95% of SSc.
The presence of scleroderma-specific antibodies may confirm SSc diagnosis, 
anti-topoisomerase I predicts diffuse SSc, but only 10% of SRC has anti-topoisom-
erase I positivity [6, 29] (Figure 6).
Anti-RNA polymerase III is a scleroderma-specific antibody and is seen only in 
diffuse scleroderma. About 24–33% of these patients develop SRC [30–32]. It was 
showed that anti-RNA polymerase is strongly associated with SRC, OR 6.4 [33]. 
This statement is valid with the exception of geographical variability. For exam-
ple, the difference in prevalence of autoantibodies among SRC patients between 
the Italian and other population might originate from the lower prevalence of 
anti-RNA polymerase III among Italians [34]. Anti-RNA polymerase III is associ-
ated with worse prognosis of SRC including Dialysis, persistence on dialysis, and 
survival [1].
Figure 6. 
Diagram showing subsets of systemic sclerosis associated with kidney involvement stratified by antibodies. 
Colored areas represent approximated proportion in patients. Adapted from Kuwana M and Medsger A [35]. 
SSc, systemic sclerosis; SRC, dSSc, diffuse cutaneous systemic sclerosis; lSSc, limited cutaneous systemic sclerosis; 
scleroderma renal crisis; anti-RNA polymerase III, anti-ribonucleic acid polymerase III antibodies; ANCA, 
anti-neutrophil cytoplasmic antibodies; anti-ds DNA, antibodies against double-stranded (ds) DNA.
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2.8.2 Microangiopathic hemolytic anemia and thrombocytopenia
SRC is a disease characterized by thrombotic microangiopathy with typical 
blood laboratory findings—new or worsening anemia, presence of schistocytes or 
other red blood cell fragments in peripheral blood smear, and thrombocytopenia 
<100.000, confirmed by manual smear. Typical features are laboratory evidence of 
hemolysis, including elevated lactate dehydrogenase, reticulocytosis, and/or low/
absent haptoglobin and negative direct anti-globulin test. In differential diagnosis, 
other types of thrombotic microangiopathies need to be excluded (see Table 3). In 
some cases, thrombotic thrombocytopenic purpura has been reported in sclero-
derma patients, but it is unclear whether it was an isolated coexisting disease or a 
different interpretation of SRC [1, 6, 36].
2.9 Differential diagnosis of scleroderma renal crisis
The most common differential diagnoses are
• anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis,
• lupus nephritis, and
• diseases associated with thrombotic microangiopathy (Table 4).
Thrombotic thrombocytopenic purpura (TTP) /hemolytic-uremic syndrome 
(HUS)/disseminated intravascular coagulation (DIC)/heparin-induced thrombo-
cytopenia (HIT)/ pre-eclampsia or HELLP syndrome refers to an acronym used to 
describe the clinical condition that leads to hemolysis, elevated liver enzymes, and 
low platelets/catastrophic antiphospholipid syndrome (CAPS), etc. [37].
Other differential diagnoses reported included membranous and membranop-
roliferative nephropathies, other vasculitis (including polyarteritis nodosa, mixed 
cryoglobulinemia, and Goodpasture syndrome), drug-induced nephropathies (due 
to D-penicillamine or cyclosporin A), oxalate nephropathy, renal artery stenosis, 
and pre-renal causes (e.g., sepsis and dehydration) [10].
2.10 Management of scleroderma renal crisis
2.10.1 Prevention
Despite significant decrease in incidence of SRC, no reliable preventive measures 
were identified. To decrease the risk of SRC development, we have to identify 
patients at high risk. Risk factors are discussed above (see chapter “Predictive and 
Risk Factors“), and we should take special caution in patients with dSS in the early 
stages of the disease (less than 5 years from diagnosis) with rapid progression of 
skin thickening, palpable tendon friction rubs, and anti-RNAP III antibodies [39]. 
Clinically, most important modifiable factor seems to be glucocorticoid treatment. 
Doses as high as 15 mg of prednisone are associated with increased incidence of 
SRC in several studies (see below).
Patients at risk should have their blood pressure controlled well. However, 
ACE inhibitors that are recommended for SRC treatment have not been shown 
to have protective effect before SRC onset and do not improve outcome of SRC 
[18, 19]. On the other hand, there are some reports of negative impact of ACE 
inhibitors on worse outcome of SRC, if ACE inhibitors were used in prevention 
of SRC [1, 40].
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History and 
condition
Scleroderma renal 
crisis
CAPS TTP-HUS HELLP 
syndrome
Sepsis DIC HIT
Previous history Systemic sclerosis APS/SLE/malignancy/
pregnancy
Malignancy/
non
pregnancy infection Infection/
malignancy
Heparin exposure
Thrombosis Small vessels Large/small vessels Small vessels Small vessels Large/small 
vessels
Small vessels Large/small 
vessels
Hemolytic anemia + −/+ ++ + −/+ −/+ —
Schistocytes + −/+ ++ + −/+ −/+ —
Fibrinogen Normal/high Normal/high Normal/high Normal/high Normal/low Normal/low Normal/high
Typical antibodies anti-RNA polymerase 
III
aPL ADAMTS13 None None None Anti-PF-4
TTP, thrombotic thrombocytopenic purpura; HUS, hemolytic uremic syndrome; DIC, disseminated intravascular coagulation; HELLP, hemolysis, elevated liver enzymes and low platelets syndrome; HIT, 
heparin-induced thrombocytopenia; APS, antiphospholipid syndrome; CAPS, catastrophic antiphospholipid syndrome; SLE, systemic lupus erythematosus; aPL, antiphospholipid antibodies; ADAMTS13, a 
disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; PF-4, platelet factor 4.
Table 3. 
Differential diagnosis of thrombotic microangiopathies from the view of scleroderma renal crisis. Adapted from Cervera et al. [37].
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Therefore, other antihypertensive drugs should be used to treat primary hyperten-
sion in these patients. Calcium channel blockers are a preferred option, as these drugs 
are effective in controlling blood pressure and a positive vasodilatory effect [41].
2.10.2 Early diagnosis
Early diagnosis and treatment can significantly improve prognosis of the 
patients. Patients at risk should be instructed to monitor blood pressure at home at 
least twice a week. They should report sudden increase in blood pressure and blood 
pressure above 140/90 mmHg. These patients should have their blood pressure 
quickly normalized and should be evaluated for possible SRC development (evalua-
tion of kidney function, presence of MAHA, etc.).
2.10.3 Treatment of scleroderma renal crisis
Current treatment of SSc focuses on broad-spectrum immunosuppression or 
organ-based therapy for separate manifestations such as lung fibrosis, skin and 
gastrointestinal involvement, pulmonary or systemic hypertension, and kidney 
impairment [1]. The treatment of SRC is based on three main principles: causal 
treatment with ACE inhibitors, methods of renal function replacement, and plasma 
exchange in some patients. For organ complications, supportive treatment is used. 
SRC without treatment is often lethal. SRC patients should be treated immediately 
and aggressively with hospitalization and under careful control (Figure 7) [1]. It is 
advisable to admit patients with symptomatic hypertension to intensive care units.
2.10.3.1 Angiotensin-converting enzyme inhibitors
The key to improved outcome is treatment with ACE inhibitors. It should be 
initiated as soon as possible. Captopril is the preferred option. It has been used in 
Event Differences from SRC
Essential hypertension Without acute renal failure
ANCA-associated glomerulonephritis ANCA positivity, significant Proteinuria, 
hematuria [38]
Overlaps with connective tissue disease with 
glomerulonephritis (SLE)
Anti-dsDNA positivity, other CTD-specific 
antibodies
Renal artery stenosis Absence of systemic symptoms
Thrombotic microangiopathies
Pre-eclampsia Pregnancy
Hemolytic uremic syndrome Shigella toxin
Thrombocytic thrombocytopenic purpura ADAMTS13 antibody
Catastrophic antiphospholipid syndrome Antiphospholipid antibodies
Heparin-induced thrombocytopenia Heparin treatment
Other conditions: membranous nephropathy, drug-induced nephropathies (e.g., cyclosporin A), other vasculitis 
(e.g., polyarteritis nodosa, mixed cryoglobulinemia, and Goodpasture syndrome), oxalate nephropathy, 
membranoproliferative nephropathy, pre-renal causes (e.g., sepsis, dehydration, and cardiac or pulmonary vascular 
involvement), and isolated renal abnormalities. SRC, scleroderma renal crisis; ANCA, antibodies against neutrophils; 
SLE, systemic lupus erythematosus; CTD, connective tissue diseases; ADAMTS13, a disintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 13.
Table 4. 
Differential diagnosis of scleroderma renal crisis. Adapted from Bose et al. [6].
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most studies and its short-acting character enables good titration at the start of the 
treatment. It is usually necessary to use very high doses. Blood pressure should be 
brought back to normal levels within 2–4 days.
ACE inhibitors have complex effect and decrease blood pressure and plasma 
renin activity. The dramatic response to therapeutic inhibition of the renin-
angiotensin system in SRC implicates renin overproduction as a central part of the 
pathogenesis of SRC [1, 42].
Several cohort studies showed benefit in survival with the use of ACE inhibitors 
in patients with SRC. The experts recommend immediate use of ACE inhibitors in 
the treatment of SRC [11, 17–19, 29, 43–48]. Prospective analysis of 108 patients 
with SRC has suggested that patients on ACE inhibitors (captopril in 47 and enala-
pril in 8) had a significantly better 1 year survival rate (76%) and 5 years (66%) 
compared to patients without ACE inhibitors (15% at one and 10% at 5 years, 
respectively). Treatment with ACE inhibitors was significantly associated with 
better survival in SRC, after adjustment for age and blood pressure (p < 0.001) [29, 
49, 50]. Two recent retrospective studies including 91 and 110 patients with SRC, 
respectively, the majority of whom (91 and 98% respectively) were treated with 
ACE inhibitors and/or angiotensin receptor antagonists (ARA), reported survival 
rates from 71–82% at 1 year, 59–60% at 5 years, and 42–47% at 10 years [19, 47]. 
Other anti-hypertensive agents may be considered for management of refractory 
hypertension in conjunction with an ACE inhibitor in SRC, including ARA, calcium 
channel blockers, doxazosin, and clonidine [1, 49]. Beta-blockers are not appropri-
ate, as they affect peripheral circulation.
It can be summarized that survival benefit was shown with the use of ACE 
inhibitors in patients with SRC. Experts recommend immediate use of ACE inhibi-
tors in the treatment of SRC [17].
Figure 7. 
Management of scleroderma renal crisis, adapted from Lynch et al. [50]. ACEi, angiotensin-converting enzyme 
inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; HDU, 
high dependency unit; ITU, intensive therapy unit; MAP, mean arterial pressure; SBP, systolic blood pressure.
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2.10.3.2 Acute kidney injury
A patient with SRC is, from a definition, the one with acute kidney injury and 
should be managed in cooperation with a nephrologist. Thus, recommendation 
for acute kidney injury should be applied including regular monitoring of kidney 
function, minimization of nephrotoxic medication, etc. During first days of SRC 
treatment, serum creatinine levels usually increase. This is an anticipated decrease 
in glomerular filtration that should not discourage us from intensive blood pressure 
control [27].
Renal replacement therapy should be initiated if necessary. Both hemodialysis 
and peritoneal dialysis are possible alternatives. However, hemodialysis is a pre-
ferred option. ACE inhibitor treatment should continue long term, even in patients 
on chronic renal replacement therapy, especially in patients with possible recovery 
of renal function.
In chronic hemodialysis patients, kidney transplantation has to be considered. 
There are two particular details in SSc patients that should be discussed: first, there 
is a possibility of late recovery of kidney function and, second, there is historically 
reported bad outcome of transplanted SSc patients. Indeed, patients with SRC may 
recover renal function up to 3 years after the crisis, most often within 12–18 months 
[50]. Thus, many authors recommend that decision to transplant should not be 
made before 2 years after SRC onset [17]. Patients after SRC on hemodialysis 
treatment should therefore be regularly checked for signs of recovery of kidney 
function. But in general, postponing kidney transplant in hemodialysis patients 
could worsen their prognosis. It seems prudent that in patients without significant 
residual renal function, without signs of kidney recovery and unfavorable findings 
on kidney biopsy (if done) such as vascular thrombosis and glomerular ischemic 
collapse, we consider kidney transplant in 6 months from SRC [51].
Older studies reported bad outcome of SSc patients after kidney transplant 
compared to patients with other causes of kidney failure. However, recent studies 
have shown excellent patient and graft survival [52].
Generally, on the other hand, long-term dialysis increases the risk of death. 
Independent of the underlying disease, dialysis increases the risk of infection (in 
patients undergoing peritoneal dialysis) and, over the long term, enhances the risk 
of vascular calcification and atherosclerosis. In patients on chronic dialysis, kidney 
transplantation has to be considered [53].
In a series of 260 SSc patients who underwent renal transplantation in the 
United States, their 5-year graft-survival rate was 56.7% [53]. In that study, the risk 
of SRC recurrence was higher for patients with early renal insufficiency following 
SRC onset. Recurrent SRC in the allograft may be predicted by the same previously 
described risk factors [53–55].
For those with recurrent SRC, the time of onset following transplantation is 
not known. Recurrence usually happens within the first few months to the first 
1–2 years after transplantation [53, 54].
Kidney transplantation should therefore be considered in all SSc patients with 
the need of renal replacement therapy. What has not changed over the last decade 
is that only small percentage of patients with SSc is transplanted due to severe 
extrarenal disease. Thorough work-up before enrolling a patient on waiting list is 
warranted.
Both recurrence of SRC after kidney transplantation and graft loss due to SRC 
recurrence have been reported. Recurrence rate is fortunately low (8.8%) and 
patients after kidney transplant should be monitored similarly to patients with SSc 
at high risk of SRC development [52].
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Immunosuppression given to SSc patients after kidney transplant alters the 
course of the disease. Most of the patients after kidney transplant have stable 
disease or even improve symptoms. Regarding immunosuppressive regimens after 
kidney transplant, it is difficult to make any evidence-based conclusions. Most 
patients were treated with high-dose steroids at the time of transplantation followed 
by long-term low doses in combination with calcineurin inhibitors and mycophe-
nolate mofetil. A significant number of patients were weaned from steroids with 
reasonable outcome, but recommendations cannot be made due to limited number 
of patients [52].
2.10.3.3 Plasma exchange
Plasma exchange, which has been proposed for thrombotic microangiopathy, has 
not demonstrated efficacy and should not be prescribed, with the exception of the 
rare SRC patients who might develop thrombotic microangiopathy associated with 
anti-ADAMTS-13 antibodies [54]. There are no clinical trial data for use of plasma 
exchange in SRC.
3.  Nonscleroderma renal crisis involvement of kidney in systemic 
sclerosis
3.1 Intersticial kidney changes/disease
Clinically relevant renal involvement (non-SRC) in SSc is uncommon [55]. 
Asymptomatic and slowly progressive renal involvement is present in 60–80% 
of SSc patients. In more than half of asymptomatic SSc patients, renal function 
demonstrates clinical markers of renal damage (proteinuria, elevation of serum 
creatinine, hypertension, etc.) [32, 56–58]. These patients presented with evidence 
of underlying chronic renal disease but without confounding illnesses such as 
diabetes or hypertension existing prior to the onset of their SSc. Histological find-
ings showed expressions of fibrillar collagens. In some SSc cases, drug exposure 
may explain interstitial kidney changes [6]. It is unclear whether SSc cases are 
more susceptible to this, but interstitial nephritis remains an important differential 
diagnosis.
3.2 Glomerulonephritis
Glomerulonephritis occurs in the context of overlap connective tissue disease 
or systemic vasculitis. In other words, SSc should be associated with other immu-
nopathological diseases presented by glomerulonephritis, mainly systemic lupus 
erythematosus and ANCA-associated glomerulonephritis [59].
Circulating antimyeloperoxidase antibodies have been reported in several 
patients with dcSSc associated with necrotizing and crescentic glomerulonephritis 
[1, 58]. A study of 81 SSc patients with renal impairment found 2 patients with 
lcSSc with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) along 
with circulating IgG and IgM antimyeloperoxidase antibodies. After screening for 
ANCA in SSc by indirect immunofluorescence, the levels of IgM and IgG anti-MPO 
antibodies in 8 patients (8%) with SSc were determined by ELISA [60]. In conclu-
sion, the presence of ANCA in SSc patients should predict ANCA-associated vascu-
litis. The treatment of these associated glomerulonephritis is managed according to 
the principles of treatment of the overlapping renal diseases (Figure 8).
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4. Conclusion
SRC is a rare manifestation with dramatic clinical picture and high morbidity 
and mortality. Current strategies to reduce the associated morbidity and mortal-
ity include identification of at-risk patients to aid early diagnosis. Caution should 
be exercised in diagnosis of SSc cases with serological features of renal disease 
including anti-RNA polymerase III autoantibodies, for non-SRC renal disease SLE 
serology and ANCA positivity. ACE inhibitor therapy should be lifelong in all SRC 
patients. Prompt initiation of ACE inhibitors stays a key point in SRC therapy. New 
therapeutic possibilities are needed.
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Figure 8. 
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